HypoDE Study: Dexcom CGM use resulted in a 72% Reduction in Hypoglycemic Events

HypoDE study shows that Dexcom CGM use significantly reduces hypoglycemia in MDI-treated patients with T1D at high risk for hypoglycemia.¹

Background

Continuous glucose monitoring (CGM) clinical trials to date have largely excluded individuals with severe hypoglycemia (SH) or impaired awareness of hypoglycemia (IAH). The study examines effectiveness of Dexcom G5 Mobile CGM System* use in patients on multiple daily injections (MDI) insulin therapy with a history of SH or IAH.

Objective

Evaluate the effectiveness of CGM in reducing hypoglycemic events^† among high-risk adults with type 1 diabetes treated with MDI.

Research Design/Methods

Randomized, controlled trial of 158 adults with type 1 diabetes.

Randomized, controlled trial conducted in 12 diabetes practices throughout Germany
30-week study that included a 4-week baseline data collection period, a 22-week intervention phase, and a 4-week evaluation period (weeks 22-26) Adults with type 1 diabetes treated on MDI (n=149); randomized to CGM use (n=75) with the Dexcom G5 Mobile System,* or a control group using self-monitoring of blood glucose (SMBG) (n=74)
History of IHA (Clarke score^‡4) or recent severe hypoglycemic event
Average baseline HbA1c of 58.0 mmol/L (7.5%)

Results

Dexcom CGM Use Reduced Exposure to Hypoglycemia.

Dexcom CGM group reduced the average number of hypo events by 72%^§ from baseline.

SMBG group showed minimal reduction of hypo events (13.5 events at baseline; 13.2 events at follow-up).

infographic: Rate of Hypo Events

Secondary Hypoglycemia Outcomes:

Reduced hypo events at night
Significant reduction of hypoglycemia
Reduced risk of severe hypo

HypoDE Study

Highlights:

72% reduction in average number of hypo events
Decreased average number of nighttime hypo events by more than half
Reduced risk of severe hypo
Reduced hypo-related distress
Reduced glycemic variability

*Baseline glucose data for all participants and the glucose data in the follow-up period for the SMBG group were collected using the Dexcom G4 PLATINUM CGM System, which uses the same software algorithm as the Dexcom G5 Mobile CGM System. Subjects in the CGM group used the Dexcom G5 Mobile in the treatment phase and the follow-up period. All CGM data collected in the baseline period and in the control group in the intervention period was blinded.

†Hypoglycemic event defined as glucose values ≤3.0 mmol/L (≤54 mg/dL) sustained for at least 20 minutes, preceded by a minimum of 30 minutes with glucose values >3.0 mmol/L (>54 mg/dL). Number of hypoglycemic events in baseline and follow-up phases were recorded for each patient and standardized to an incidence of hypo events per 28 days.

‡The Clarke score measures hypo awareness, based on a response to eight questions characterizing an individual's exposure to moderate and severe hypo events. Scores ≥4 indicate IHA.

§Adjusted for baseline differences.

1 Heinemann L, Freckmann G, Faber-Heinemann G, Stefania Guerra S, Ehrmann D, Waldenmaier D, Hermanns N. Benefits of continuous glucose monitoring use in adults with type 1 diabetes and impaired hypoglycaemia awareness and/or severe hypoglycaemia treated with multiple daily insulin injections: Results of the multi-centre, randomised controlled HypoDE study. Lancet. 2018 Apr 7;391(10128):1367-1377.

VIEW THE ARTICLE

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Request a Visit from a Dexcom Representative

Request a G7 Sample

Request Stelo Education Materials

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Do not include prefix (Mr., Mrs., Dr.)

As listed on Provider’s medical license (no MD, Jr., Sr.)

Please use the Provider's NPI

Please provide the facility address

Is your patient on a connected pump device?

Yes

By submitting the above form, I certify that I am a licensed practitioner, authorized to receive and dispense samples of the Dexcom G6 Continuous Glucose Monitoring System and/or Dexcom‘s next generation product, Dexcom G7 (the "Samples"). I represent that I am requesting the Samples for evaluation purposes and that I will not (i) sell, resell, barter, return for credit or seek reimbursement for the use of the Samples, or (ii) for professional services for dispensing or evaluating the Samples, I also agree to inform my patients that they should not submit claims for reimbursement to any third party for any Samples.

The Samples are FDA cleared for use with a compatible smart device or separate piece of durable medical equipment called a receiver. Neither devices nor receivers are included in the Samples. Accordingly, and in light of the applicable G6 or G7 Dexcom Instructions for Use, you should dispense Samples only to a patient who (or whose authorized caregiver), in the exercise of your clinical judgment, (i) has reliable access to a compatible smart device and/or automated insulin delivery system, and (ii) is capable of safely using the Samples with their smart device, without the need for a separate dedicated receiver.

Please note that Medicare will reimburse for sensors only if the beneficiary also uses a receiver covered by Medicare. Accordingly, it is appropriate to give Samples to Medicare patients only if they have (in the case of the G6 Samples) or would be eligible to obtain (in the case of the G7 Samples), a Medicare-covered receiver.

You agree that you will not provide the Samples to any patients that are beneficiaries under the Maine or Colorado state Medicaid programs. I understand that Dexcom will be tracking, and if necessary, reporting and may be subject to disclosure requirements with respect to the provision of these Samples. I agree not to reuse any Samples. I acknowledge that Dexcom provides no warranties for the Samples other than the warranties outlined in the applicable Dexcom Instructions for Use. I will comply with all applicable federal, state and local laws in receiving and dispensing these Samples, and I agree to store and use these Samples in a manner consistent with the applicable Dexcom Instructions for Use. Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. ©2023 Dexcom, Inc. All rights reserved.

LBL-1004145 Rev001

By submitting the above form, I certify that I am a licensed practitioner, authorized to receive and dispense these Dexcom G6 Continuous Glucose Monitoring Systems and/or Dexcom‘s next generation product, Dexcom G7 (the "Dexcom Education Devices") which are provided in the quantities listed above.

The Dexcom Education Devices are FDA cleared for use with a compatible smart device or separate piece of durable medical equipment called a receiver. Neither smart devices nor receivers are included with the Dexcom Education Devices. I understand that these Dexcom Education Devices are being requested for me and other healthcare professionals ("HCPs") for evaluation purposes to learn more about the Dexcom Education Devices and experience the benefits of the Dexcom Education Devices through a product demonstration, and that each HCP will need a compatible smart device for the product demonstration.

I acknowledge that Dexcom provides no warranties for the Dexcom Education Devices other than the warranties outlined in the applicable Dexcom Instructions for Use. I will comply with all applicable federal, state and local laws in receiving and dispensing these Dexcom Education Devices in a manner consistent with the applicable Dexcom Instructions for Use, and agree not to reuse any Dexcom Education Devices. I agree to receive, store, distribute, and/or use these Dexcom Education Devices in a manner consistent with the applicable Dexcom Instructions for Use and device labeling. I understand that Dexcom will be tracking, and if necessary, reporting and may be subject to disclosure requirements with respect to the provision of these Dexcom Education Devices. I understand and agree to properly dispose of the Dexcom Education Devices immediately following the completion of the product demonstration. The Dexcom Education Devices are being provided at no cost, without any expectation of remuneration, HCPs have no obligations under the federal supply schedule contract for participating in the product demonstration, and Dexcom waives any rights under this contract or applicable law to pursue a claim for the costs associated with the Dexcom Education Devices.

Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. ©2023 Dexcom, Inc. All rights reserved.

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.